PPT Slide

Phase 1:

Phase 2:

Phase 3:

(Labeling)

Safety / tolerability / dosing

Evidence of cholesterol mobilization

Safety / tolerability / dosing

Changes in vascular structure / function

(MRI, IVUS, brachial artery ultrasound)

Evidence of benefit:

Improvements in CV clinical outcomes

HDL Therapy

Biopharmaceutical Clinical Development

Previous slide

Next slide

Back to first slide

View graphic version